Canaccord Genuity Group Issues Positive Forecast for CeriBell (NASDAQ:CBLL) Stock Price

CeriBell (NASDAQ:CBLL) had its price objective lifted by research analysts at Canaccord Genuity Group from $30.00 to $31.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 7.45% from the stock’s previous close.

Several other research firms also recently commented on CBLL. William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective for the company. TD Cowen began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price for the company. Finally, Bank of America began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $31.20.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $28.85 on Wednesday. CeriBell has a twelve month low of $23.00 and a twelve month high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.